Send us Feedback

Progenics Pharmaceuticals (PGNX)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
Progenics Pharmaceuticals, Inc. (PGNX) Posts Q1 Loss of 22c/Share
StreetInsider.com  May 10  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Progenics+Pharmaceuticals%2C+Inc.+%28PGNX%29+Posts+Q1+Loss+of+22cShare/8325652.html for the full story.
'Mad Money' Lightning Round: I Like Priceline
TheStreet.com  Apr 2  Comment 
Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener. NEW YORK (TheStreet) -- Here's what Jim Cramer had to say about some of the stocks callers offered up during the "Mad Money Lightning...
Benzinga's Small Cap Movers for Friday March 15, 2013
Benzinga  Mar 17  Comment 
Below are highlights from Benzinga's daily coverage of small cap securities making big moves: Ambow Education Holding Shares of Ambow Education Holding (NYSE: AMBO), the China-based education company, soared 53% Friday on 13 times average...
Furious Two-Way Intel Options Action, Rite-Aid Draws In Bulls
Forbes  Mar 15  Comment 
Today?s tickers: INTC, PGNX & RAD
Unusual 11 Mid-Day Movers 03/15: (PGNX) (AMBO) (STP) Higher; (SNMX) (GLDD) (SUPN) Lower
StreetInsider.com  Mar 15  Comment 
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) 30.5% HIGHER; reported Q4 EPS of ($0.01), $0.30 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $8.87 million versus the consensus estimate of $1.16 million. Senomyx,...
Progenics Pharma (PGNX) Posts Narrower than Expected Q4 Loss
StreetInsider.com  Mar 15  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Progenics+Pharma+%28PGNX%29+Posts+Narrower+than+Expected+Q4+Loss/8187667.html for the full story.
AstraZeneca (AZN) Enters In-Lincensing Deal for Progenics' (PGNX) Clostridium Difficile Program
StreetInsider.com  Dec 17  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/AstraZeneca+%28AZN%29+Enters+In-Lincensing+Deal+for+Progenics%27+%28PGNX%29+Clostridium+Difficile+Program/7952308.html for the full story.
Progenics Pharmaceuticals (PGNX) Prices 11M Shares at $2
StreetInsider.com  Nov 29  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/Progenics+Pharmaceuticals+%28PGNX%29+Prices+11M+Shares+at+%242/7911076.html for the full story.
Progenics Pharmaceuticals, Inc. (PGNX) Misses Q3 EPS by 3c
StreetInsider.com  Nov 8  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Progenics+Pharmaceuticals%2C+Inc.+%28PGNX%29+Misses+Q3+EPS+by+3c/7856763.html for the full story.
Progenics Pharmaceuticals Initiates Phase 2 Clinical Trial of PSMA ADC in Prostate Cancer Patients
Benzinga  Sep 28  Comment 
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) has opened enrollment in a phase 2 study in prostate cancer patients of its PSMA ADC compound. PSMA ADC is a targeted anti-cancer therapeutic that uses a monoclonal antibody to deliver a cell-killing...




more ▼WIKI ANALYSIS
Error creating thumbnail: convert: unable to open image `/home/wikinvest/src_live_1/mediawiki/images/9/98/New_stock.png': No such file or directory @ blob.c/OpenBlob/2480. convert: unable to open file `/home/wikinvest/src_live_1/mediawiki/images/9/98/New_stock.png' @ png.c/ReadPNGImage/2889. convert: missing an image filename `/home/wikinvest/src_live_1/mediawiki/images/thumb/9/98/New_stock.png/35px-New_stock.png' @ convert.c/ConvertImageCommand/2800.
 The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.


 




References

Retrieved from "http://www.wikinvest.com/stock/Progenics_Pharmaceuticals_(PGNX)"
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki